Acadia pharmaceuticals acquires ex-north american rights to trofinetide and global rights to neuren's nnz-2591 in rett syndrome and fragile x syndrome

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that it has expanded its current licensing agreement for trofinetide with neuren pharmaceuticals to acquire ex-north american rights to the drug as well as global rights in rett syndrome and fragile x syndrome to neuren's development candidate nnz-2591. in april of this year, acadia launched trofinetide in the united states under the brand name daybue as the first and only drug approved for the treatment of r.
ACAD Ratings Summary
ACAD Quant Ranking